sharon sanders
Editor-in-Chief & President
Autoantibody production is enhanced after mild SARS-CoV-2 infection despite vaccination in patients with and without long COVID
View ORCID ProfileLavanya Visvabharathy, Chengsong Zhu, Zachary S Orban, Kristine Yarnoff, Nicole Palacio, Millenia Jimenez, Patrick Lim, Pablo Penaloza-MacMaster, Igor J Koralnik
doi: https://doi.org/10.1101/2023.04.07.23288243
This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
00000049
Abstract
Long COVID patients who experienced severe acute SARS-CoV-2 infection can present with humoral autoimmunity. However, whether mild SARS-CoV-2 infection provokes autoantibody responses and whether vaccination can decrease these responses in long COVID patients is unknown. Here, we demonstrate that mild SARS-CoV-2 infection increases autoantibodies associated with systemic lupus erythematosus (SLE) and inflammatory myopathies in long COVID patients with persistent neurologic symptoms to a greater extent than convalescent controls at more than 8 months post-infection. Furthermore, high titers of SLE-associated autoantibodies in long COVID patients are associated with impaired cognitive performance and greater symptom severity, and subsequent vaccination does not decrease autoantibody titers. In summary, we found that mild SARS-CoV-2 infection can induce long-term humoral autoimmunity in both long COVID patients and healthy COVID convalescents, suggesting that a reappraisal of vaccination and mitigation strategies is warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
L.V. is supported by grant B48 from the philanthropic COVID research fund through Balvi Ops. P.P.M is supported by grants from the National Institute on Drug Abuse (NIDA, DP2DA051912) and from the National Institute of Biomedical Imaging and Bioengineering (NIBIB, U54EB027049). I.K. is supported by a grant from the National Institute of Aging (NIA, R01AG059291).
View ORCID ProfileLavanya Visvabharathy, Chengsong Zhu, Zachary S Orban, Kristine Yarnoff, Nicole Palacio, Millenia Jimenez, Patrick Lim, Pablo Penaloza-MacMaster, Igor J Koralnik
doi: https://doi.org/10.1101/2023.04.07.23288243
This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
00000049
Abstract
Long COVID patients who experienced severe acute SARS-CoV-2 infection can present with humoral autoimmunity. However, whether mild SARS-CoV-2 infection provokes autoantibody responses and whether vaccination can decrease these responses in long COVID patients is unknown. Here, we demonstrate that mild SARS-CoV-2 infection increases autoantibodies associated with systemic lupus erythematosus (SLE) and inflammatory myopathies in long COVID patients with persistent neurologic symptoms to a greater extent than convalescent controls at more than 8 months post-infection. Furthermore, high titers of SLE-associated autoantibodies in long COVID patients are associated with impaired cognitive performance and greater symptom severity, and subsequent vaccination does not decrease autoantibody titers. In summary, we found that mild SARS-CoV-2 infection can induce long-term humoral autoimmunity in both long COVID patients and healthy COVID convalescents, suggesting that a reappraisal of vaccination and mitigation strategies is warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
L.V. is supported by grant B48 from the philanthropic COVID research fund through Balvi Ops. P.P.M is supported by grants from the National Institute on Drug Abuse (NIDA, DP2DA051912) and from the National Institute of Biomedical Imaging and Bioengineering (NIBIB, U54EB027049). I.K. is supported by a grant from the National Institute of Aging (NIA, R01AG059291).